AgomAb Therapeutics NV - ADRs representing one common share

CEO Tim Knotnerus has led Agomab since 2019 with prior BD experience; CMO Philippe Wiesel brings fibrosis development expertise; CFO Pierre Kemula previously served as CFO at CureVac, adding public‑company and financing depth. The board is being augmented in 2026 with experienced industry leaders.

Overall execution to date on financing, regulatory alignment, and trial progress is solid, though the team still must demonstrate pivotal‑stage execution and commercial build capabilities.